MENU
+Compare
IDXG
Stock ticker: OTC
AS OF
Oct 3 closing price
Price
$0.92
Change
+$0.08 (+9.52%)
Capitalization
3.71M

IDXG stock forecast, quote, news & analysis

Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features... Show more

IDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for IDXG with price predictions
Oct 03, 2025

IDXG's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IDXG turned positive on September 16, 2025. Looking at past instances where IDXG's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2025. You may want to consider a long position or call options on IDXG as a result. In of 129 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

IDXG moved above its 50-day moving average on October 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IDXG crossed bullishly above the 50-day moving average on October 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXG advanced for three days, in of 179 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where IDXG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IDXG broke above its upper Bollinger Band on September 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IDXG entered a downward trend on September 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.455). P/E Ratio (3.036) is within average values for comparable stocks, (136.052). IDXG's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.777). IDXG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.505) is also within normal values, averaging (9.153).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IDXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 11.61B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 3%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 36%. GRAL experienced the highest price growth at 31%, while BIAF experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -61%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 68
Price Growth Rating: 55
SMR Rating: 81
Profit Risk Rating: 90
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
IDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of commercialization services to biopharmaceutical companies

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
2001 Route 46
Phone
+1 855 776-6419
Employees
108
Web
https://www.interpace.com